

Tassos Georgiou and Ekatherine Prokopiou

Introduction

Over the last few decades, there is an increasing interest in the role of omega-3 polyunsaturated fatty acids (PUFAs) and chronic inflammation. Numerous evidence exist from pre-clinical and clinical studies which prove the effectiveness of omega-3 PUFAs against heart disease, cancer, diabetes, neurological and autoimmune diseases [1]. This chapter will mainly focus on the role of omega-3 PUFAs in maintaining or improving the vision of different eye pathologies (either investigated in vivo or in a clinical setting), including age-related macular degeneration, macular dystrophies and severe dry eyes. In particular, emphasis will be given on the anti-inflammatory effect of omega-3 PUFAs. Also, some observational results from our patients are presented and future directions regarding how to benefit from the omega-3 PUFAs are briefly discussed.

Polyunsaturated Fatty Acids

Currently, several studies have been focusing on the therapeutic role of omega-3 PUFAs, which are considered anti-inflammatory molecules. The resolution of inflammation is an active process primarily driven by a new family of mediators, termed resolvins, derived from the omega-3 PUFAs, eicosapentaenoic acid (EPA, C20:5 ω -3) and docosahexaenoic acid (DHA, C22:6 ω -3) [2]. These PUFAs are highly concentrated in the brain and retina and have an important role in the neuronal development and damage repair [3]. DHA is abundantly expressed in the photoreceptors, and vital retinal functions depend on its existence [4].

T. Georgiou (✉) · E. Prokopiou
Ophthalmos Research and Educational Institute, 48 Morfou,
Engomi, Nicosia, 2417, Cyprus
e-mail: tassosgeorgiou@hotmail.com

E. Prokopiou
e-mail: prokopiou.k@unic.ac.cy

Among the major mediators of the inflammatory response is the generation of pro-inflammatory eicosanoids generated from the omega-6 PUFA, arachidonic acid (AA, C20:4 ω -6). These include pro-inflammatory prostaglandins (e.g. PGE₂) and leukotrienes (e.g. LTB₄), which can act as mediators for leucocyte chemotaxis and inflammatory cytokine production. The balance between the pro- and anti-inflammatory molecules plays a key role in the disease progression and the resolution of an inflammatory response.

Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. It is estimated that 200 million people suffer worldwide and the number of these individuals is going to be increased up to 50 % by 2040 [5, 6]. The main symptom of early AMD is blurring of central vision which results in difficulty in reading and recognising faces. There are two different types of AMD: the dry form which is the most common one and occurs in 9 in 10 cases, and the wet form (choroid neovascularisation, CNV) which occurs in about 1 in 10 cases. In dry AMD, the retinal pigment epithelium (RPE) cells of the macula, which are crucial for the function of the rods and cones, will gradually degenerate. In wet AMD, in addition to the RPE cells' degeneration, newly formed blood vessels grow from the choroid, break through Bruch's membrane and migrate into the macula part of the retina. These vessels are immature and leak fluid within the retina resulting in scarring of the macula and damage of the rods and cones [7, 8].

Pathogenesis of Age-Related Macular Degeneration

Currently, there is no definite cause for the pathogenesis of AMD, but several different aetiologies. Ageing is one of the most common contributing factors of AMD, due to the

accumulation of oxidised lipoproteins and free radicals in the retina and choroid. This in turn results in oxidative stress and a decrease in the number of RPE cells and photoreceptors [9, 10]. In addition to oxidative stress, natural age advancement also leads to immunosenescence which is the gradual deterioration of the immune system, specifically the T-cell population [11, 12].

Genetic predisposition, as with multiple pathologies, plays a role in the development of AMD; although there are several genetic associations, the most studied ones are some polymorphic links, in particular related to inflammatory genes, such as the *complement factor H (CFH)* and some complement components (e.g. *C3* and *C2*) [13, 14]. The *CFH* gene which controls the activation of the complement system through the alternative pathway was found to be associated with an increased risk of developing AMD [15, 16]. Environmental factors, including smoking, sunlight exposure, high-fat diet, obesity and diabetes, are all associated with the development and progression of AMD [17].

Para-Inflammation in Age-Related Macular Degeneration

Furthermore, a tissue adaptive response, recently described as para-inflammation, where the innate immune system mount a low-grade inflammatory response in order to restore tissue homeostasis, has been implicated in the pathogenesis of AMD [18, 19]. In particular, chronic inflammatory infiltrates, such as macrophages, lymphocytes and mast cells, have been detected in the choroid of AMD eye donors [20, 21]. Inflammatory-related proteins, including C-reactive protein (CRP) [22–25], interleukin-6 (IL-6) [25, 26] and tumour necrosis factor- α (TNF- α) [25, 27], have been associated with AMD; however, the results from different groups are inconsistent. The fact that systemic inflammatory markers are not strongly related to AMD might suggest that local low-grade inflammation is more likely to be involved in the pathogenesis of AMD. In addition, resident retinal microglia were found to be activated in the outer nuclear layer, in regions of ongoing photoreceptor cell death, in patients with AMD, retinitis pigmentosa and late-onset retinal degeneration [28]. The microglia cell activation is an indication of an immune response to ocular injury or inflammation, as well as retinal degeneration. During normal ageing and also in pathological conditions, such as AMD, there is an observed accumulation of microglia in the sub-retinal space, localised in the areas of RPE cell death. Apart from microglia activation, complement activation is also involved in ageing and in both forms of AMD. It is suggested that the damage of RPE cells and photoreceptors in AMD may, at least in part, be caused directly by complement activation at the retinal/choroidal interface [29, 30].

Evidence demonstrated that a local complement regulatory system exists in the eye, by the detection of complement components, such as the C3, membrane cofactor protein (MCP), decay-acceleration factor (DAF), membrane inhibitor of reactive lysis (CD59) and cell surface regulator of complement (Crry) [31, 32].

Treatment Options for Age-Related Macular Degeneration

With regards to the wet AMD, treatment options are based on anti-VEGF (vascular endothelial growth factor) therapies which aim to attenuate angiogenesis and vascular permeability. However, this type of targeted therapy does not lead to complete vascular or disease regression [33]. To assess the long-term outcomes, Rofagha et al. investigated the effect of intensive ranibizumab therapy in exudative AMD patients 7–8 years after initiation of the treatment. One-third of the patients demonstrated good visual outcomes 7 years post-treatment, whereas another third had poor outcomes. Almost half of the eyes were stable, whereas one-third declined by 15 letters or more and 37 % ended blind despite numerous injections [34]. These results may indicate that even a long-term therapeutic regime does not reduce the risk for substantial visual decline.

In contrast, for the dry form of AMD, there are no current guidelines for the first-line treatment, although several anti-oxidants, vitamins and zinc may reduce its progression according to the Age-related Eye Disease Study (AREDS). This study was a major clinical trial sponsored by the National Eye Institute which was designed to evaluate the effect of high doses of vitamin C (500 mg), vitamin E (400 international units), β -carotene (15 mg), zinc (80 mg) and copper (2 mg) on the progression of AMD and cataract [35].

Following the AREDS, an additional study was performed, the AREDS2, which was a multi-centre five-year randomised trial, designed to examine the effects of oral supplementation of macular xanthophylls (10 mg lutein and 2 mg zeaxanthin) and/or omega-3 PUFAs (650 mg EPA and 350 mg DHA) on the progression to advanced AMD. Overall, there was no additional benefit from adding the omega-3 PUFAs or a mixture of lutein and zeaxanthin to the formulation. Although the addition of omega-3 to the AREDS formulation was not proven beneficial, it is believed that higher doses of EPA and DHA may have a desirable effect.

To further examine the association of omega-3 dietary intake (from fish sources) with incidents of late-stage AMD (both neovascular and geographic atrophy), SanGiovanni et al. estimated nutrient and food intake from a validated food frequency questionnaire in AREDS participants. The data obtained indicated that people who were consuming the

highest levels of EPA and EPA + DHA had a 50 % reduced likelihood in disease progression (from bilateral drusen to central geographic atrophy) [36]. This shows a clear correlation between the dietary lipid intake and the development of AMD into a more severe clinical presentation.

Therefore, the inconclusive results from the clinical studies led to further investigations in order to examine the possible mechanisms of action of the omega-3 PUFAs and to assess any positive outcomes with regards to the disease progression.

Current Research in Age-Related Macular Degeneration

Numerous in vitro studies demonstrated that treatment of endothelial cells with omega-3 PUFAs effectively inhibited pro-inflammatory responses through modulation of nuclear factor- κ B (NF- κ B), TNF- α and interleukin-1 β (IL-1 β)-induced cell adhesion molecule (CAM) expression [37–40].

Dry Age-Related Macular Degeneration

Furthermore, several animal studies focused on the dietary supplementation of omega-3 PUFAs in murine models for macular degeneration. In particular, Tuo et al. reported the therapeutic effect of a high omega-3 diet in the *Ccl2*^{-/-}/*Cx3cr1*^{-/-} double knockout model, which develops focal retinal lesions with certain features of AMD [41]. The high omega-3 diet included 1.9 wt % of each EPA and DHA, 0.66 wt % α -linolenic acid (α -LNA) and 0.4 wt % docosapentaenoic acid (DPA). The omega-6/omega-3 ratio was 2.9, where the omega-6 source was from the linoleic acid (LA) only. Specifically, animals that ingested a high omega-3 diet for up to 8 months of age showed progression of retinal lesions compared with the low omega-3 diet group. This effect was suggested to be through a reduction in the AA metabolism, as demonstrated by the decreased pro-inflammatory derivatives (PGE₂ and LTB₄). High levels of dietary omega-3 PUFAs may result in the incorporation of EPA into cell membrane phospholipids at the expense of AA, leading to less substrate available for eicosanoid synthesis [42]. In contrast to PGE₂, higher serum levels of PGD₂ (an anti-inflammatory mediator [43]) were observed in the high omega-3 PUFAs group, indicating a protective effect against inflammation. In addition, there was lower ocular TNF- α and IL-6 transcript levels in the high omega-3 group, suggesting that reactive mediators of omega-3 PUFAs may also regulate differential gene expression [41].

Following treatment with the AREDS2 formulation, Ramkumar et al. reported its effect on the *Ccl2*^{-/-}/*Cx3cr1*^{-/-} model [44]. This formulation included high doses of

omega-3 PUFAs (54.9 mmol EPA/kg diet and 25.2 mmol DHA/kg diet), 17.6 mmol lutein/kg diet and 1.76 mmol zeaxanthin/kg diet. After 3 months of treatment, the animals fed with the high omega-3 PUFAs diet showed significant lesion regression, following fundoscopic examination and a great reduction in the ocular A2E concentration (a fluorophore found in lipofuscin and RPE phagolysosomes). Morphological changes were noted, where the outer nuclear layer thickness was greater in the high omega-3-treated group than that in the control one. The retinal expression of pro-inflammatory mediators, including TNF- α , Cyclooxygenase-2 (*Cox-2*), IL-1 β , VEGF and inducible nitric oxide synthase (*iNos*), was much lower in the high omega-3-treated group compared with the control. The AA concentration in the retina was found to be lower and the EPA higher in the high omega-3 group compared to the control, whereas the retina AA/EPA ratio was estimated to be 2.26. However, the serum concentration of PGE₂ which is a metabolite of AA did not significantly differ between the two groups [44]. This fact may indicate that the concentration of fatty acids (and their metabolites) in the serum and retina is not directly correlated.

Observational Studies in Age-Related Macular Degeneration

In addition to the preclinical studies, an open-label pilot study performed by Georgiou et al. investigated the therapeutic effect of controlled doses of high omega-3 PUFAs in patients with dry AMD. The supplement formulation included 3.4 g EPA and 1.6 g DHA, where patients followed this treatment on a daily basis for 6 months. Significant improvement in visual acuity was observed in all patients with dry AMD, and by 4.5 months of treatment, all patients had gained a minimum of 1 line of vision consisting of 5 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and a third of patients gained 3 lines consisting of 15 letters [45].

Further observational studies took place with 24 eyes of twelve patients with dry AMD, both sexes and mean age of 75, where they were supplemented with 15 ml of omega-3 formulation divided into two daily doses. The omega-3 concentrates consisted of purified ethyl esters rich in EPA (400 mg) and DHA (200 mg) per gram for the liquid formulation. The dosage used in this pilot study provided approximately 5 g EPA and 2.5 g DHA per day. Patients were asked to continue with their current diet as normal and not to increase their consumption of food containing essential fatty acids.

Follow-up was performed at 1.5, 3, 4.5 and 6 months. Visual acuity was examined at each follow-up using the ETDRS chart, and the blood AA/EPA ratio was measured prior and during treatment using a gas chromatographic




Fig. 20.1 The effect of omega-3 supplementation on **a** visual acuity in patients with dry AMD according to the letters gained and **b** the AA/EPA ratio pre-treatment and during treatment

technique. The optimum AA/EPA ratio is believed to be between 1 and 2 for maximum anti-inflammatory effects. The mean initial visual acuity of patients was 6/18 + 2 (36 %). The mean gain of letters at 1.5, 3, 4.5 and 6 months was 3.8 ± 0.7 , 7.3 ± 1.2 , 13.3 ± 2.3 and 16.0 ± 2.6 , respectively (Fig. 20.1a). The mean AA/EPA ratio prior to treatment was estimated to be 7.2 ± 0.6 , whereas during the period of treatment was reduced to 1.7 ± 0.1 (Fig. 20.1b). No side effects were reported by any of the patients treated in the study. The closer the AA/EPA to 1, the more pronounced the effect was.

Wet Age-Related Macular Degeneration

Additional animal studies have been performed using models of wet AMD and other ocular pathologies, including retinal angiogenesis or diabetic retinopathy. Yanai et al. demonstrated that metabolites derived from the omega-3 PUFAs, which are generated through the cytochrome P450 (CYP450), are potent inhibitors of intraocular neovascular disease, such as wet AMD [46]. It is known that the omega-6 PUFAs, including AA, generate CYP-metabolites, the epoxyeicosatrienoic acids (EETs), which are associated with the VEGF-activated signalling cascade, leading to angiogenesis [47]. On the other hand, the CYP-generated metabolites of EPA and DHA, namely 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and 19,20-epoxydocosapentaenoic acid (19,20-EDP), respectively, have shown anti-angiogenic

properties [48]. Therefore, Yanai et al. investigated the dietary enrichment with omega-3 PUFAs in a mouse model of laser-induced CNV and demonstrated suppression of CNV (possibly through increased expression of peroxisome proliferator-activated receptor- γ , PPAR- γ), vascular leakage, immune cell recruitment and adhesion molecules (E-selectin and intracellular adhesion molecule-1, Icam-1) to the lesion site. In addition, VEGF expression was suppressed in the retina and choroid of the mice fed with the high omega-3 diet. A significant increase in the serum levels of anti-inflammatory eicosanoids was observed in the high omega-3 group, which was mediated through the CYP-metabolites, 17,18-EEQ and 19,20-EDP [46].

Similar studies by Connor et al. were previously performed, evaluating the therapeutic effects of omega-3 PUFAs on hypoxia-induced pathological neovascularisation in a mouse model of oxygen-induced retinopathy [49]. The results suggested that by increasing the level of omega-3 PUFAs either by dietary or genetic means (using *Fat-1* transgenic model which converts omega-6 to omega-3 PUFAs), there was a reduced hypoxic stimulus for neovascularisation. This effect was mediated through the bioactive metabolites neuroprotectin D1, resolvin D1 and resolvin E1, through reduction in the TNF- α expression which was found to be present in a subset of microglia within the retinal vessels [49].

Furthermore, in a clinical setting, Renzende et al. examined the effect of omega-3 PUFAs supplementation (1052 mg fish oil, 600 mg EPA and DHA) on the levels of vitreous VEGFA, in patients with wet AMD who were receiving intravitreal anti-VEGF therapy. Interestingly, the group of patients that was supplemented with omega-3 showed lower levels of VEGFA in the vitreous but similar levels in the plasma compared to the other groups [50]. This indicates that omega-3 PUFAs could also be useful in minimising progression of wet AMD.

Retinitis Pigmentosa

Retinitis pigmentosa (RP) refers to an inherited, genetically heterogeneous condition which can result from mutations in several different genes (>45 known genes), including the rhodopsin and cyclic guanosine monophosphate phosphodiesterase (cGMP) β -subunit genes [51–53]. RP is affecting approximately 1 in 3500 people pan-ethnically and is a major cause of blindness in adults [54]. What drives the disease progression is the dysregulation and degeneration of the photoreceptors through apoptotic signals, initiating from the rods followed by the cones at a later stage. The main characteristics of RP are night blindness, retinal pigmentary deposit [55] and gradual loss of peripheral vision. As the degeneration of the photoreceptors progress, the vision loss will be increased leading to eventual blindness.

Inflammation plays an important role in the pathogenesis of RP as demonstrated by Newsome et al. who found inflammatory cells infiltrate into the vitreous cavity of RP patients [56]. In addition, Yoshida et al. investigated the inflammatory response in the aqueous humour and vitreous fluid of RP patients by examining different pro-inflammatory cytokines and chemokines performed by ELISA analysis. There was a significant increase of MCP-1 and IL-8 in the aqueous humour, whereas in vitreous fluid, there was an increase in a variety of cytokines/chemokines, including IL-1 α , IL-1 β and MCP-1 [57].

Current Research in Retinitis Pigmentosa

At present, there is no available treatment which targets the regression of RP; thus, numerous studies are ongoing. The necessity of omega-3 fatty acids for proper retina functioning was demonstrated by Bush et al., where a reduced capacity for photoabsorption by rhodopsin could play a role in lowering retinal sensitivity to light in omega-3 PUFAs-deficient rats [58]. Omega-3 PUFAs and some anti-oxidants or vitamins have been used in several laboratory and clinical studies in order to examine their effect on RP progression, aiming to reduce inflammation.

The nature of the inflammatory response in the rd10 model of RP was evaluated by Yoshida et al., who found an increased expression of pro-inflammatory cytokines/chemokines in the retina, activated microglia and photoreceptor apoptosis. However, treatment of animals with an anti-oxidant, N-acetylcysteine (NAC), prevented the photoreceptor cell death and reduced the inflammatory response [59].

In addition, the effect of DHA was examined in a mouse model of inherited retinal degeneration (Rslh^{-Y}). Supplementation of animals with DHA demonstrated enhancement of the photoreceptors' survival, transformation of the activated microglia to a quiescent phenotype and reduction in the pro-inflammatory gene expression [60]. This indicated that the retinal DHA levels could control the activity of microglia and perhaps the extent of retinal degeneration.

A randomised, controlled, double-masked trial was performed in order to determine the effect of DHA in patients with RP receiving vitamin A treatment. Patients were given either 1200 mg/day of DHA or control capsules over a 4-year period, in addition to vitamin A. The end results showed that supplementation of DHA over a 4-year interval did not slow the course of disease in RP patients [61]. Similar disappointing results were obtained by a different clinical trial using DHA supplementation (400 mg/day) with X-linked RP patients [62]. In contrast, Berson et al. analysed questionnaires completed by patients with RP who were receiving vitamin A for 4–6 years. The difference in visual acuity was compared between those with high (≥ 0.20

g/day) versus low (<0.2 g/day) omega-3 intake. The study concluded that patients receiving vitamin A and who consumed a diet rich in omega-3 fatty acids had slower decline in visual acuity than those who consumed a low omega-3 diet [63].

An overview of the clinical findings was presented by Hodge et al. which analysed 6 different studies involved investigation of the intake of omega-3 fatty acids. The review suggests that the data obtained from those studies did not provide a conclusive result as to whether or not the intake of omega-3 fatty acids could slow the progression of RP [64].

Stargardt Disease

The most common form of autosomal recessive macular dystrophy is Stargardt disease which affects the RPE and photoreceptor layer and is usually associated with mutations in the *ABCA4* gene (ATP-binding cassette 4) [65], which leads to accumulation of lipofuscin [66]. Stargardt disease is characterised by a juvenile onset (first two decades), a rapidly progressive course and a poor visual outcome. Loss in central vision is observed caused by a progressive central atrophy.

Another type of macular dystrophy is the autosomal dominant Stargardt-like macular dystrophy type 3 (STGD3), which is caused by 3 sets of mutations in the *ELOVL4* gene (elongation of very long chain fatty acids protein 4) [67, 68]. The *ELOVL4* protein is involved in fatty acids' elongation which is necessary for the generation of long chain PUFAs [69]. Mouse models and human clinical studies indicated that a deficiency of very long chain PUFAs in the retina is likely to be a key factor in the macular pathology seen in STGD3 [70, 71].

Current Research in Stargardt Disease

The effect of omega-3 supplementation is believed to play a role in the disease progression. In particular, Dornstauder et al. used the *ELOVL4* transgenic model (which displays extensive age-related retina dysfunction and A2E accumulation), to study the effect of dietary DHA supplementation. The data obtained indicated that following DHA supplementation for several months (starting at different stages), there was preserved retina function at mid-degenerative stages and reduced A2E levels in the mouse models [72]. Furthermore, Querques et al. reported a study where 840 mg/day DHA was given to 20 late-onset Stargardt disease patients for six months. A complete ophthalmological examination was performed pre- and post-treatment. The evidence from the study demonstrated

that DHA influenced some functional parameters in those patients; however, there was not significant short-term benefit [73].

Additionally, some emerging therapeutic options for Stargardt disease are being considered, including drugs which modify the functional activity of ABCA4 protein [74], which slow down the visual cycle [75] or gene-targeted therapy [76, 77].

Cone Dystrophies

Cone dystrophies are associated with genetic mutations (e.g. guanylate cyclase activating protein 1, *GCAP1*) which result in functional abnormalities in the cone photoreceptors and sometimes in their post-receptor pathways [78]. This could be inherited as an autosomal recessive, autosomal dominant or X-linked recessive trait. Within these types of dystrophies, there are subtypes including the stationary cone dystrophy and the progressive (cone-rod dystrophy) which have a different time of the disease presentation. All forms of cone dystrophies show reduced visual acuity and colour vision deficiency, along with dysfunction of the cone electrophysiology [79, 80]. Although these are inherited disorders, chronic inflammation is an important component that contributes to the disease progression. Shiose et al. demonstrated the involvement of Toll-like receptor 3 (TLR3) in a cone-rod dystrophy animal model lacking the ABCA4 and RDH8 proteins (which are critical for all-trans-retinal clearance in the retina). These findings suggested that endogenous products from degenerating retina can stimulate TLR3, causing apoptosis and retinal inflammation. In addition, the loss of TLR3 showed a protective effect from cone-rod dystrophy [81].

Observational Studies in Macular Dystrophies

The strong evidence from the literature regarding the positive outcomes from the supplementation of omega-3 PUFAs in retinopathies and following the promising results from the preliminary study with dry AMD patients [45] led us to investigate the effect of omega-3 in patients with macular dystrophies. Observational studies included a total of 40 eyes of 21 patients with macular dystrophies, 9 patients with Stargardt disease with mean age of 33.6 ± 6.1 , 6 patients with RP with mean age of 54.2 ± 6.4 and 6 patients with cone dystrophies and mean age of 41.3 ± 4.4 . Patients were supplemented twice daily with an omega-3 formulation, and follow-up was performed at 1.2, 3, 4.5 and 6 months. RP patients were supplemented with 5 g/day of EPA/DHA (ratio 2:1), and the Stargardt's and cone dystrophy patients




Fig. 20.2 The effect of omega-3 supplementation on **a** visual acuity in patients with macular dystrophies according to the letters gained and **b** the AA/EPA ratio pre-treatment and during treatment

were supplemented with 7.5 g/day of EPA/DHA (ratio 2:1). Visual acuity was examined at each follow-up using the ETDRS chart, and the blood AA/EPA ratio was monitored. The mean initial visual acuity of all patients was 6/18 (33%). The overall mean gain of letters for all types of macular dystrophies at 1.2, 3, 4.5 and 6 months was 5.2 ± 0.9 , 9.7 ± 1.1 , 10.5 ± 0.9 , 11.2 ± 0.9 , respectively (Fig. 20.2a). The mean AA/EPA ratio pre-treatment in patients with macular dystrophies was 9.9 ± 0.6 , while during treatment, the ratio was reduced to 1.4 ± 0.09 (Fig. 20.2b).

Severe Dry Eyes

Dry eye disease is a multifactorial disorder of the tears and ocular surface that represents one of the most prevalent ocular conditions, and it is a frequent reason that people seek eye care [82]. Dry eye disease is caused by disequilibrium of tear film components and results in symptoms of chronic ocular discomfort, functional visual disturbance that interferes with quality of life [83–85]. Around 3.2 million women in the USA aged 50 years and older have dry eye disease [86], and depending on the population, age and definition, the estimates of the prevalence of dry eyes in the general population range from <1% to 30% [83, 87].

Although there has been some progress in understanding the natural history of dry eye disease, current treatment

options for severe dry eye disease have limited efficacy and there are no means of prevention. Artificial tears are the standard of care for the treatment of dry eyes [88]. However, they can provide only temporary symptom control and they do not affect the causative factors of the inflammation that occurs in dry eyes. As a result, artificial tears may only be suited for milder dry eye disease [89]. In more severe disease, multiple treatments are often required, in particular one survey of treating ophthalmologists found that patients with severe dry eye disease usually need to use around five different treatment approaches to manage this condition [90], with the most frequently used treatment being artificial tears, followed by anti-inflammatory drugs and secretagogues [89].

Restasis® (0.05 % cyclosporine ophthalmic emulsion; Allergan) is the only pharmacologic treatment approved by the FDA to increase tear production, but its licensed indication does not extend to the treatment of the symptoms associated with dry eye disease. The onset of action is 24 weeks and many patients are intolerant due to side effects, particularly ocular burning sensation, which occurs in up to 17 % of treated patients [91].

Inflammation, particularly of the ocular surface and meibomian glands, is thought to be an important contributor in the pathogenesis of dry eye disease [92, 93]. Patients with dry eye disease have an increased concentration of inflammatory molecules (such as TNF- α , VEGF, IFN- γ , IL-1, IL-6, epidermal growth factor and fractalkine) in the tear film [93]. Inflammation can be relieved by topical steroids and anti-inflammatory drugs, but most are unsuitable for long-term use and their use may be limited by side effects [94]. There is a clear need for additional options to provide continuous relief of severe dry eye disease symptoms and that are acceptable to patients.

Several studies have suggested that omega-3 PUFAs (including α -LA, EPA and DHA) systemic and topical administration is effective as adjunctive therapy in dry eye disease [95–100]. Possible mechanisms suggested effects on tear secretion, prevention of oxidative damage and reduction in inflammation.

In a cross-sectional observational study, Milanović et al. found that the prevalence of dry eyes was substantially lower among women who had a higher intake of omega-3 PUFAs, compared with those with a lower intake, where the prevalence was higher [95]. In this study, intake of omega-3 PUFAs was estimated by a questionnaire of dietary intake. To date, most studies to investigate omega-3 supplements in dry eye disease have been limited in design and size, and the doses of omega-3 PUFAs have varied, making meaningful comparisons difficult. There is a need for additional trials using omega-3 PUFAs to provide the evidential basis for their use as an adjunct to current therapies for dry eye disease.

Observational Studies in Severe Dry Eyes

We hypothesised that high-dose omega-3 PUFAs may provide a viable alternative treatment for dry eye disease. Therefore, an observational study was performed in order to investigate this hypothesis, where patients with severe dry eyes who had not responded to other standard treatment were supplemented with 10 ml of omega-3 formulation (providing approximately 3.4 grams of EPA and 1.6 grams of DHA per day). The dosage was divided into two daily doses of 5 ml each. Sixty eyes of 30 patients with dry eyes were included in the study, 26 females and 4 males, with mean age of 58 ± 9.9 years. Patients were asked to continue with their current diet as normal, and not to increase their consumption of food containing essential fatty acids. Visual acuity using the ETDRS chart, tear break-up time and fluorescein staining score was determined prior to the initiation of the study and then at 1.5 and 3 months post-treatment.

Eyes that had the greatest gain in visual acuities were those who started with the worst initial vision. The patients who had reduced vision (e.g. 6/15 or worse) had a significant ($p < 0.05$) improvement in vision (Fig. 20.3a). Prior to the omega-3 supplementation, the fluorescein staining was either moderate (17 %) or severe (83 %) in all patients, whereas at




Fig. 20.3 a Number of ETDRS chart lines gained at 3 months in patients with severe dry eyes and b corneal fluorescein staining scores following supplementation with an omega-3 formulation




Fig. 20.4 Improvement in tear film break-up time in patients with severe dry eyes following supplementation with an omega-3 formulation for 3 months

the end of the study, no eye had severe staining, and only one eye had moderate staining, illustrating that staining scores improved significantly ($p < 0.001$, Fig. 20.3b). Tear break-up time increased significantly from a mean of 1.78–4.4 s at 3 months ($p < 0.001$, Fig. 20.4). No side effects were reported by any of the patients treated in the study.

In summary, evidence from the literature and from our observational studies suggest that supplementation with high doses of omega-3 PUFAs of patients with retinopathies and severe dry eyes results in disease regression by a substantial improvement in visual acuity. A point for consideration is the monitoring of the AA/EPA ratio, where this could not only provide the optimum therapeutic effect (between 1 and 2) but it could also prevent undesirable side effects by remaining in the safety range (≥ 1).

Conclusions

Chronic low-grade inflammation attacks the body's organs for years until enough damage occurs to produce a chronic disease. It is inflammation below the threshold of pain which is not initially noticeable until chronic organ damage occurs. As for the eyes, reduced vision is the first obvious symptom. Anti-inflammatory drugs, such as steroids and non-steroidal anti-inflammatory drugs (NSAIDs), could reduce chronic inflammation; although side effects such as gastric bleeding, immunosuppression, osteoporosis and heart failure do not make them ideal agents for long-term use. In addition, substantial long-term improvement in visual acuity has not been demonstrated with this class of drugs. Maintaining the AA/EPA ratio between 1 and 2 using omega-3 supplementation could provide an excellent therapeutic regimen for reducing inflammation in the retina and the optic nerve with no side effects. Further studies are ongoing in order to get a better optimisation of the anti-inflammatory effect of omega-3 PUFAs and to have an improved understanding on their mechanism of action and their long-term effects.

References

1. Sears B. The anti-inflammation zone. New York: HarperCollins; 2005.
2. Serhan CN, Arita M, Hong S, Gotlinger K. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. *Lipids*. 2004;39(11):1125–32.
3. Bazan NG. Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection. *Current Opin Clin Nutr Metab Care*. 2007;10(2):136–41.
4. Birch EE, Birch DG, Hoffman DR, Uauy R. Dietary essential fatty acid supply and visual acuity development. *Invest Ophthalmol Vis Sci*. 1992;33(11):3242–53.
5. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al. Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol*. 2004;122(4):564–72.
6. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. *Lancet Glob Health*. 2014;2(2):e106–16.
7. Miller JW. Age-related macular degeneration revisited—piecing the puzzle: the LXIX Edward Jackson memorial lecture. *Am J Ophthalmol*. 2013;155(1):1–35, e13.
8. SanGiovanni JP, Agron E, Clemons TE, Chew EY. Omega-3 long-chain polyunsaturated fatty acid intake inversely associated with 12-year progression to advanced age-related macular degeneration. *Arch Ophthalmol*. 2009;127(1):110–2.
9. Nag TC, Wadhwa S. Ultrastructure of the human retina in aging and various pathological states. *Micron*. 2012;43(7):759–81.
10. Harman D. Aging: a theory based on free radical and radiation chemistry. *J Gerontol*. 1956;11(3):298–300.
11. Nussenblatt RB, Lee RW, Chew E, Wei L, Liu B, Sen HN, et al. Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention. *Am J Ophthalmol*. 2014;158(1):5–11, e2.
12. Macaulay R, Akbar AN, Henson SM. The role of the T cell in age-related inflammation. *Age*. 2013;35(3):563–72.
13. Ferrara DC, Merriam JE, Freund KB, Spaide RF, Takahashi BS, Zhitomirsky I, et al. Analysis of major alleles associated with age-related macular degeneration in patients with multifocal choroiditis: strong association with complement factor H. *Arch Ophthalmol*. 2008;126(11):1562–6.
14. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. *Prog Retinal Eye Res*. 2010;29(2):95–112.
15. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. *Science*. 2005;308(5720):385–9.
16. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. *Science*. 2005;308(5720):421–4.
17. Gottfredsdottir MS, Sverrisson T, Musch DC, Stefansson E. Age related macular degeneration in monozygotic twins and their spouses in Iceland. *Acta Ophthalmol Scand*. 1999;77(4):422–5.
18. Xu H, Chen M, Forrester JV. Para-inflammation in the aging retina. *Prog Retinal Eye Res*. 2009;28(5):348–68.
19. Barouch FC, Miller JW. The role of inflammation and infection in age-related macular degeneration. *Int Ophthalmol Clin*. 2007;47(2):185–97.
20. Penfold PL, Killingsworth MC, Sarks SH. Senile macular degeneration: the involvement of immunocompetent cells. *Graefe's Arch Clin Exp Ophthalmol*. 1985;223(2):69–76

- (Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie).
21. Penfold PL, Liew SC, Madigan MC, Provis JM. Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration. *Invest Ophthalmol Vis Sci.* 1997;38(10):2125–33.
 22. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. *JAMA.* 2004;291(6):704–10.
 23. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. *Arch Ophthalmol.* 2005;123(6):774–82.
 24. Klein R, Klein BE, Marino EK, Kuller LH, Furberg C, Burke GL, et al. Early age-related maculopathy in the cardiovascular health study. *Ophthalmology.* 2003;110(1):25–33.
 25. Klein R, Klein BE, Knudtson MD, Wong TY, Shankar A, Tsai MY. Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. *Am J Ophthalmol.* 2005;140(1):35–44.
 26. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. *Am J Med.* 2004;116(Suppl 6A):9S–16S.
 27. Cousins SW, Espinosa-Heidmann DG, Csaky KG. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? *Arch Ophthalmol.* 2004;122(7):1013–8.
 28. Gupta N, Brown KE, Milam AH. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. *Exp Eye Res.* 2003;76(4):463–71.
 29. Chen M, Forrester JV, Xu H. Synthesis of complement factor H by retinal pigment epithelial cells is down-regulated by oxidized photoreceptor outer segments. *Exp Eye Res.* 2007;84(4):635–45.
 30. Chen M, Muckersie E, Robertson M, Forrester JV, Xu H. Up-regulation of complement factor B in retinal pigment epithelial cells is accompanied by complement activation in the aged retina. *Exp Eye Res.* 2008;87(6):543–50.
 31. Coffey PJ, Gias C, McDermott CJ, Lundh P, Pickering MC, Sethi C, et al. Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. *Proc Natl Acad Sci USA.* 2007;104(42):16651–6.
 32. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. *Invest Ophthalmol Vis Sci.* 2000;41(11):3492–502.
 33. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Group VISIONCT. Pegaptanib for neovascular age-related macular degeneration. *New Engl J Med.* 2004;351(27):2805–16.
 34. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). *Ophthalmology.* 2013;120(11):2292–9.
 35. Age-Related Eye Disease Study Research G. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. *Arch Ophthalmol.* 2001;119(10):1439–52.
 36. SanGiovanni JP, Chew EY, Agron E, Clemons TE, Ferris FL 3rd, Gensler G, et al. The relationship of dietary omega-3 long-chain polyunsaturated fatty acid intake with incident age-related macular degeneration: AREDS report no. 23. *Arch Ophthalmol.* 2008;126(9):1274–9.
 37. Mishra A, Chaudhary A, Sethi S. Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway. *Arterioscler Thromb Vasc Biol.* 2004;24(9):1621–7.
 38. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. *Am J Clin Nutr.* 2000;71(1 Suppl):213S–23S.
 39. Chen W, Esselman WJ, Jump DB, Busik JV. Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. *Invest Ophthalmol Vis Sci.* 2005;46(11):4342–7.
 40. Rotstein NP, Politi LE, German OL, Girotti R. Protective effect of docosahexaenoic acid on oxidative stress-induced apoptosis of retina photoreceptors. *Invest Ophthalmol Vis Sci.* 2003;44(5):2252–9.
 41. Tuo J, Ross RJ, Herzlich AA, Shen D, Ding X, Zhou M, et al. A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. *Am J Pathol.* 2009;175(2):799–807.
 42. Calder PC. Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. *Braz J Med Biol Res.* 2003;36(4):433–46 (Revista brasileira de pesquisas medicas e biologicas/ Sociedade Brasileira de Biofisica).
 43. Kapoor M, Kojima F, Yang L, Crofford LJ. Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. *Prostaglandins Leukot Essent Fatty Acids.* 2007;76(2):103–12.
 44. Ramkumar HL, Tuo J, de Shen F, Zhang J, Cao X, Chew EY, et al. Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background. *J Nutr.* 2013;143(7):1129–35.
 45. Tassos Georgiou AN, Nicolaou Despina, Sears Barry. Pilot study for treating dry age-related macular degeneration (AMD) with high-dose omega-3 fatty acids. *PharmaNutr.* 2014;2:8–11.
 46. Yanai R, Mulki L, Hasegawa E, Takeuchi K, Sweigard H, Suzuki J, et al. Cytochrome P450-generated metabolites derived from omega-3 fatty acids attenuate neovascularization. *Proc Natl Acad Sci USA.* 2014;111(26):9603–8.
 47. Webler AC, Michaelis UR, Popp R, Barbosa-Sicard E, Murugan A, Falck JR, et al. Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. *Am J Physiol Cell Physiol.* 2008;295(5):C1292–301.
 48. Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, et al. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. *Proc Natl Acad Sci USA.* 2013;110(16):6530–5.
 49. Connor KM, SanGiovanni JP, Lofqvist C, Aderman CM, Chen J, Higuchi A, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. *Nat Med.* 2007;13(7):868–73.
 50. Rezende FA, Lapalme E, Qian CX, Smith LE, SanGiovanni JP, Sapienza P. Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration. *Am J Ophthalmol.* 2014;158(5):1071–8.
 51. Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW, et al. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. *Nature.* 1990;343(6256):364–6.
 52. Kajiwara K, Hahn LB, Mukai S, Travis GH, Berson EL, Dryja TP. Mutations in the human retinal degeneration slow gene in autosomal dominant retinitis pigmentosa. *Nature.* 1991;354(6353):480–3.
 53. Cotran PR, Bruns GA, Berson EL, Dryja TP. Genetic analysis of patients with retinitis pigmentosa using a cloned cDNA probe for

- the human gamma subunit of cyclic GMP phosphodiesterase. *Exp Eye Res.* 1991;53(5):557–64.
54. Wong P. Apoptosis, retinitis pigmentosa, and degeneration. *Biochemistry Cell Biol.* 1994;72(11–12):489–98 (*Biochimie et biologie cellulaire*).
 55. Pruett RC. Retinitis pigmentosa: clinical observations and correlations. *Trans Am Ophthalmol Soc.* 1983;81:693–735.
 56. Newsome DA, Michels RG. Detection of lymphocytes in the vitreous gel of patients with retinitis pigmentosa. *Am J Ophthalmol.* 1988;105(6):596–602.
 57. Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, et al. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. *Ophthalmology.* 2013;120(1):100–5.
 58. Bush RA, Malnoe A, Reme CE, Williams TP. Dietary deficiency of N-3 fatty acids alters rhodopsin content and function in the rat retina. *Invest Ophthalmol Vis Sci.* 1994;35(1):91–100.
 59. Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, et al. Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. *Ophthalmology.* 2013;120(1):e5–12.
 60. Ebert S, Weigelt K, Walczak Y, Drobnik W, Mauerer R, Hume DA, et al. Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration. *J Neurochem.* 2009;110(6):1863–75.
 61. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Moser A, Brockhurst RJ, et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. *Arch Ophthalmol.* 2004;122(9):1297–305.
 62. Hoffman DR, Locke KG, Wheaton DH, Fish GE, Spencer R, Birch DG. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. *Am J Ophthalmol.* 2004;137(4):704–18.
 63. Berson EL, Rosner B, Sandberg MA, Weigel-DiFranco C, Willett WC. omega-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. *Arch Ophthalmol.* 2012;130(6):707–11.
 64. Hodge WG, Barnes D, Schachter HM, Pan YI, Lowcock EC, Zhang L, et al. The evidence for efficacy of omega-3 fatty acids in preventing or slowing the progression of retinitis pigmentosa: a systematic review. *Can J Ophthalmol.* 2006;41(4):481–90 (*Journal canadien d'ophtalmologie*).
 65. Allikmets R. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. *Nat Genet.* 1997;17(1):122.
 66. Delori FC, Staurengli G, Arend O, Dorey CK, Goger DG, Weiter JJ. In vivo measurement of lipofuscin in Stargardt's disease—Fundus flavimaculatus. *Invest Ophthalmol Vis Sci.* 1995;36(11):2327–31.
 67. Bernstein PS, Tammur J, Singh N, Hutchinson A, Dixon M, Pappas CM, et al. Diverse macular dystrophy phenotype caused by a novel complex mutation in the ELOVL4 gene. *Invest Ophthalmol Vis Sci.* 2001;42(13):3331–6.
 68. Molday RS, Zhang K. Defective lipid transport and biosynthesis in recessive and dominant Stargardt macular degeneration. *Prog Lipid Res.* 2010;49(4):476–92.
 69. Guillou H, Zdravcov D, Martin PG, Jacobsson A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. *Prog Lipid Res.* 2010;49(2):186–99.
 70. Barabas P, Liu A, Xing W, Chen CK, Tong Z, Watt CB, et al. Role of ELOVL4 and very long-chain polyunsaturated fatty acids in mouse models of Stargardt type 3 retinal degeneration. *Proc Natl Acad Sci USA.* 2013;110(13):5181–6.
 71. Agbaga MP, Brush RS, Mandal MN, Henry K, Elliott MH, Anderson RE. Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. *Proc Natl Acad Sci USA.* 2008;105(35):12843–8.
 72. Dornstauder B, Suh M, Kuny S, Gaillard F, Macdonald IM, Clandinin MT, et al. Dietary docosahexaenoic acid supplementation prevents age-related functional losses and A2E accumulation in the retina. *Invest Ophthalmol Vis Sci.* 2012;53(4):2256–65.
 73. Querques G, Benlian P, Chanu B, Leveziel N, Coscas G, Soubrane G, et al. DHA supplementation for late onset Stargardt disease: NAT-3 study. *Clin Ophthalmol.* 2010;4:575–80.
 74. Sun H, Molday RS, Nathans J. Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease. *J Biol Chem.* 1999;274(12):8269–81.
 75. Maiti P, Kong J, Kim SR, Sparrow JR, Allikmets R, Rando RR. Small molecule RPE65 antagonists limit the visual cycle and prevent lipofuscin formation. *Biochemistry.* 2006;45(3):852–60.
 76. Gouze E, Pawliuk R, Pilapil C, Gouze JN, Fleet C, Palmer GD, et al. In vivo gene delivery to synovium by lentiviral vectors. *Molecular Ther J Am Soc Gene Ther.* 2002;5(4):397–404.
 77. Kostic C, Chiodini F, Salmon P, Wiznerowicz M, Deglon N, Hornfeld D, et al. Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina. *Gene Ther.* 2003;10(9):818–21.
 78. Jiang L, Baehr W. GCAP1 mutations associated with autosomal dominant cone dystrophy. *Adv Exp Med Biol.* 2010;664:273–82.
 79. Simunovic MP, Moore AT. The cone dystrophies. *Eye.* 1998;12(Pt 3b):553–65.
 80. Moore AT. Cone and cone-rod dystrophies. *J Med Genet.* 1992;29(5):289–90.
 81. Shiose S, Chen Y, Okano K, Roy S, Kohno H, Tang J, et al. Toll-like receptor 3 is required for development of retinopathy caused by impaired all-trans-retinal clearance in mice. *J Biol Chem.* 2011;286(17):15543–55.
 82. Lemp MA. Management of dry eye disease. *Am J Manag Care.* 2008;14(3 Suppl):S88–101.
 83. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. *Am J Manag Care.* 2008;14(3 Suppl):S102–6.
 84. Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. *Current Ophthalmol Rep.* 2013;1(2):51–7.
 85. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. *Ophthalmology.* 2003;110(7):1412–9.
 86. Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. *Am J Ophthalmol.* 1997;124(6):723–8.
 87. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workshop. *The Ocular Surface.* 2007;5(2):75–92.
 88. Tong L, Petznick A, Lee S, Tan J. Choice of artificial tear formulation for patients with dry eye: where do we start? *Cornea.* 2012;31(Suppl 1):S32–6.
 89. Alves M, Fonseca EC, Alves MF, Malki LT, Arruda GV, Reinach PS, et al. Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. *Ocul Surf.* 2013;11(3):181–92.
 90. Asbell PA, Spiegel S. Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey. *Trans Am Ophthalmol Soc.* 2009;107:205–10.
 91. Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. *Clin Ophthalmol.* 2008;2(4):829–36.

92. Enriquez-de-Salamanca A, Castellanos E, Stern ME, Fernandez I, Carreno E, Garcia-Vazquez C, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. *Mol Vis*. 2010;16:862–73.
93. McDermott AM, Perez V, Huang AJ, Pflugfelder SC, Stern ME, Baudouin C, et al. Pathways of corneal and ocular surface inflammation: a perspective from the cullen symposium. *Ocul Surf*. 2005;3(4 Suppl):S131–8.
94. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. *Br J Ophthalmol*. 2008;92(4):455–9.
95. Miljanovic B, Trivedi KA, Dana MR, Gilbard JP, Buring JE, Schaumberg DA. Relation between dietary n-3 and n-6 fatty acids and clinically diagnosed dry eye syndrome in women. *Am J Clin Nutr*. 2005;82(4):887–93.
96. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). *Trans Am Ophthalmol Soc*. 2008;106:336–56.
97. Brignole-Baudouin F, Baudouin C, Aragona P, Rolando M, Labetoulle M, Pisella PJ, et al. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. *Acta Ophthalmol*. 2011;89(7):e591–7.
98. Rashid S, Jin Y, Ecoiffier T, Barabino S, Schaumberg DA, Dana MR. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. *Arch Ophthalmol*. 2008;126(2):219–25.
99. Kawakita T, Kawabata F, Tsuji T, Kawashima M, Shimmura S, Tsubota K. Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial. *Biomed Res*. 2013;34(5):215–20.
100. Kangari H, Eftekhari MH, Sardari S, Hashemi H, Salamzadeh J, Ghassemi-Broumand M, et al. Short-term consumption of oral omega-3 and dry eye syndrome. *Ophthalmology*. 2013;120(11):2191–6.